Sponsors should be aware of the significant implications the Addendum is likely to have on clinical trial planning, conduct, statistical analysis, and interpretation.
Ülker Aydemir
Advertisement
Articles by Ülker Aydemir
Advertisement
Latest Updated Articles
- Estimands and Implications for Sponsors as ICH E9 (R1) Addendum Progresses
Published: December 13th 2017 | Updated:
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Integrating AI Across Legacy Clinical Trial Systems
2
Reimagining Clinical Operations Through Artificial Intelligence
3
Balancing Human Oversight and Automation in AI-Driven Trials
4
Preparation Tips to Minimize Impact of Regulatory Inspections for IRT Systems
5
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
